Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, February 2001, p. 413-419, Vol. 45, No. 2
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.2.413-419.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Plasmid Location and Molecular Heterogeneity of the
L1 and L2
-Lactamase Genes of Stenotrophomonas
maltophilia
Matthew B.
Avison,*
Catherine S.
Higgins,
Charlotte J.
von Heldreich,
Peter M.
Bennett, and
Timothy R.
Walsh
Bristol Centre for Antimicrobial Research and
Evaluation (BCARE), Department of Pathology and Microbiology, School of
Medical Sciences, University of Bristol, Bristol BS8 ITD, United
Kingdom
Received 16 March 2000/Returned for modification 1 July
2000/Accepted 30 October 2000
 |
ABSTRACT |
An approximately 200-kb plasmid has been purified from clinical
isolates of Stenotrophomonas maltophilia. This plasmid was found in all of the 10 isolates examined and contains both the L1 and
the L2
-lactamase genes. The location of L1 and
L2 on a plasmid makes it more likely that they could spread
to other gram-negative bacteria, potentially causing clinical problems. Sequence analysis of the 10 L1 genes revealed three novel genes, L1c, L1d, and L1e, with 8, 12, and 20%
divergence from the published strain IID 1275 L1
(L1a), respectively. The most unusual L1 enzyme (L1e)
displayed markedly different kinetic properties, with respect to
hydrolysis of nitrocefin and imipenem, compared to those of L1a (250- and 100-fold lower
kcat/Km ratios
respectively). L1c and L1d, in contrast, displayed levels of hydrolysis
very similar to that of L1a. Several nonconservative amino acid
differences with respect to L1a, L1b, L1c, and L1d were observed in the
substrate binding-catalytic regions of L1e, and this could explain the
kinetic differences. Three novel L2 genes (L2b, L2c, and
L2d) were sequenced from the same isolates, and their
sequences diverge from the published sequence of strain IID 1275 L2 (L2a) by 4, 9, and 25%, respectively. Differences in L1 and L2 gene sequences were not accompanied by similar
divergences in 16S rRNA gene sequences, for which differences of <1%
were found. It is therefore apparent that the L1 and L2 genes have
evolved relatively quickly, perhaps because of their presence on a plasmid.
 |
INTRODUCTION |
In recent years there have been
major increases in the frequencies with which certain, previously rare
bacterial species have been identified as the causes of
hospital-acquired bacteremias (26). Three principle
factors have combined to bring about this change: (i) increased numbers
of hospitalized patients who are severely immunosuppressed; (ii) an
increase in complicated surgical procedures, such as transplant and
oncology surgery, and the use of intravenous catheters; and (iii) the
prophylactic use of antibiotics, particularly
-lactams
(26). A prime example of such an emergent pathogen is
Stenotrophomonas maltophilia (6, 11, 25, 26, 28). Its tolerance to silver-lined catheters (28)
and its inherent resistance to many antibacterial drugs, including
most, if not all,
-lactams (1, 26, 27), give it a
survival advantage over other potential pathogens in the hospital
environment. Its incidence as a cause of nosocomial bacteremias caused
by gram-negative organisms is now second only to that of bacteremia
caused by Pseudomonas aeruginosa, and the frequency of its
isolation is increasing (25). It is also a significant
cause of bacterial infection among young adults with cystic fibrosis
(10).
The mechanisms of antibacterial drug resistance in S. maltophilia have not been studied in detail, but it is expected
that many of the acquired mechanisms found in P. aeruginosa
and other gram-negative bacteria are likely to be present. Strains that are resistant to all known aminoglycosides, quinolones,
-lactams, chloramphenicol, rifampin, tetracycline, and trimethoprim have been
reported (1, 26, 27). Resistance to these agents is by a
combination of intrinsic and acquired determinants. Resistance to
-lactams is primarily intrinsic, mediated by two inducible
-lactamases, L1 and L2 (10, 18, 21-23). L1 is a
Zn2+-dependent metalloenzyme that hydrolyzes virtually all
classes of
-lactams, including penicillins, cephalosporins, and
carbapenems but excluding monobactams (9, 18, 22, 30),
while L2 is a serine active-site cephalosporinase (23,
31). On the basis of the fact that
-lactamase expression in
S. maltophilia is inducible and intrinsic to the bacterial
species, the assumption has been that the L1 and L2 genes are
chromosomal, although this has not been rigorously tested.
Recent reports have indicated that the S. maltophilia
species currently accommodates strains that show significant degrees of
evolutionary divergence, as reflected by DNA hybridization studies and
16S rRNA gene (rDNA) sequence analyses (7, 13). In fact,
sequence divergence of as much as 30% was found (13). Although strain variations in the amino acid sequences of both L1 and
L2
-lactamases are indicated by isoelectric focusing analysis (10, 19, 20), there is a paucity of information as to how differences in pI values relate to differences in the amino acid sequences. Little is known about allelic variation among L1 and L2
genes. Allelic variation creates a set of natural mutants of a
particular gene, and analysis of their products can help us understand
the biochemical mechanics of the reaction catalyzed. In the case of the
-lactamases of S. maltophilia, it was hoped that such an
investigation would facilitate greater understanding of the L1 enzyme
in particular.
The work described here was undertaken, therefore, to determine the
extent of allelic variation among L1 and L2
-lactamase genes from 10 clinical isolates of S. maltophilia collected on an oncology
ward over a period of several years. The primary aims were to assess
whether the degrees of change of L1 and L2 are essentially the same in each isolate and to investigate the effect of
consequent amino acid variation on enzyme activity. In addition, the
locations of L1 and L2 were determined and a
comparison of the extent of L1 and L2 variation
and that seen in the corresponding 16S rRNA genes from the isolates was made.
 |
MATERIALS AND METHODS |
Bacterial strains.
Ten clinical isolates of S. maltophilia were collected over several years from bacteremic
oncology patients undergoing treatment at a hospital in Bristol, United
Kingdom. The criteria for selection of the isolates were that the
patients had recurrent bacteremia which had not responded to
piperacillin-tazobactam and ceftazidime therapy. The isolates were
plated on nutrient agar (Oxoid plc., Basingstoke, United Kingdom) to
confirm their purity, and their identities were validated with API 20NE
test strips (BioMerieux, La Balme les Grottes, France). Details about
the individual strains are given in Table
1.
Materials.
Unless otherwise stated, all media used were
either nutrient broth or nutrient agar (Oxoid plc.). PCR primers were
purchased from Sigma-Genosys Ltd. (Pampisford, United Kingdom). The
-lactams used were nitrocefin (Beckton-Dickinson, Cockeysville, Md.)
and imipenem (Merck Sharpe & Dohme, West Point, Pa.). All other general reagents were from Sigma Chemical Co. or BDH, both of Poole, United Kingdom.
PCR and DNA sequencing.
Five microliters of purified plasmid
DNA or 20 µl of genomic DNA was used as a template for PCR analysis.
Plasmid DNA was isolated with a Hybaid Plasmid Recovery kit (Hybaid,
Teddington, United Kingdom) according to the manufacturer's
instructions. Genomic DNA was purified and standard PCR was performed
as described previously (14). For multiplex PCR, 1 µM
each primer was used in the same reaction mixture. In all cases an
annealing temperature of 60°C was used. The primer sets used in this
study were L1-FULL forward (5'-ACCATGCGTTCTACCCTGCTCGCCTTCGCC-3')
and reverse (5'-TCAGCGGGCCCCGGCCGTTTCCTTGGCCAG3'); L2-FULL forward (5'-CGATTCCTGCAGTTCAGT3') and reverse
(5'-CGGTTACCTCATCCGATC-3'); L2-MID forward
(5'CGATGATCACCAGCGACA-3') and reverse
(5'-CGGTTACCTCATCCGATC-3'); rDNA forward
(5'-TCAGATTTGAACGCTGGCGGCA-3') and reverse
(5'-CGTATTACCGCGGCTGCTGCCAC-3'), and D-PEP forward
(5'-CGCAACCTGTGGGTGATC-3') and reverse
(5'-CCAGATCGTTCTCGACCA-3'). The L1-FULL, L2-FULL, and D-PEP
primers flank the first and final codons of the published L1
(30), L2 (31), and dipeptidyl peptidase IV
(15) genes respectively. The L2-MID primers amplify an
internal 500-bp fragment of the L2 gene sequence. The rDNA primers bind to highly conserved sequences in the 16S rRNA gene and amplify a 500-bp
fragment of the gene for which the majority of sequence variation is
known to occur in different gram-negative bacteria (17).
In some cases, PCR products were purified with a QIAquick PCR
purification kit (Qiagen Ltd., Crawley, United Kingdom), and both
strands were sequenced with an ABI Prism 377 automatic sequencer (Perkin-Elmer, Warrington, United Kingdom) by use of dye termination chemistry according to the manufacturer's instructions. DNA and protein sequences were compared by using the Lasergene suite of programs (DNASTAR Inc., Madison, Ws.).
Overexpression and purification of L1.
The L1a gene,
originally cloned from strain IID 1275 on plasmid pUB5811
(30), was amplified by PCR, as described above, by using
pUB5811 as the template. The L1c, L1d, and L1e genes were similarly
amplified by using S. maltophilia isolate K279a, J675a, or
N531 genomic DNA, respectively, as the template. The resultant
amplicons were individually TA cloned into the pTrcHis2-TOPO vector
(Invitrogen, Carlsbad, Calif.), and recombinant molecules were
transformed into Escherichia coli TOP10 One Shot competent cells (Invitrogen), according to the manufacturer's guidelines, to
produce separate clones representing the four L1 isoforms. The presence
of L1 in ampicillin-resistant clones was confirmed by PCR,
and one of each positive clone was used to inoculate separate broth
cultures, which were grown (37°C, with shaking) until an optical
density at 600 nm of 0.5 to 0.6 was reached.
Isopropyl-
-D-thiogalactopyranoside (IPTG) (final
concentration, 1 mM) was then added to each culture to induce L1
overproduction, and growth continued for a further 3 h. The cells
were pelleted by centrifugation (4,000 × g, 20 min,
4°C) and resuspended in buffer A (50 mM cacodylate [pH 6.0] containing 10 µM ZnCl2, 0.02% [wt/vol] sodium azide, 1 mM
-mercaptoethanol). Lysozyme was added (to 200 µg/ml), and each
mixture was incubated (10 min, 20°C). CaCl2 was then
added (final concentration, 10 mM) to stabilize the spheroplasts, and
cell debris was pelleted by centrifugation (9,000 × g,
20 min, 4°C). The supernatants ware filtered with Stericup filters
(Millipore, Watford, United Kingdom) to remove insoluble matter, and in
separate purification procedures, each was applied to an SP-Sepharose
column (Amersham Pharmacia Biotech) equilibrated with buffer A. In each
case, L1 was eluted with a 0 to 1 M NaCl gradient in buffer A, and
fractions containing L1 were pooled and concentrated (Centricon 10 concentrator; Amicon, Stonehouse, United Kingdom). L1 was then further
purified with a Superdex 200 gel filtration column (Amersham Pharmacia
Biotech) by using buffer A containing 100 mM NaCl.
Production of crude cell extracts for
-lactamase assay.
E. coli recombinants containing the L1 clones
were grown separately in broth. Induction of L1 expression with IPTG
was performed as described above. The cells were pelleted, and extracts
for
-lactamase assay were prepared as described previously
(2).
-Lactamase assays and steady-state kinetic analysis.
Hydrolysis of
-lactam antibiotics was examined by spectrophotometric
analysis (Pharmacia LKB Ultraspec III; Pharmacia, St Albans, United
Kingdom), with readings recorded at 2-s intervals for 3 min at the
wavelength associated with the largest difference in absorbance upon
hydrolysis of the
-lactam ring of each drug, i.e., 482 and 299 nm,
for nitrocefin and imipenem, respectively. Antibiotic solutions were
prepared in 50 mM cacodylate (pH 7.0) containing 100 µM
ZnCl2. The rate of hydrolysis (v) of each
-lactam was calculated for at least five different concentrations of
substrate (S) by using 17,400 and 7,000 AU · M
1 · cm
1 as extinction coefficients
for hydrolysis of nitrocefin and imipenem, respectively. A plot of
S/v against S was used to calculate
Vmax (1/slope) and Km
(x intercept multiplied by Vmax). The
monomeric kcat (in seconds
1) of L1
for each substrate was determined by dividing
Vmax by the concentration of L1 monomer in the
assay. The monomer concentration was determined by using the extinction
coefficients (at 280 nm) for a monomer of L1a (38,930 AU · M
1 · cm
1) and L1e (38,930 AU
· M
1 · cm
1), which were calculated
from their amino acid sequences with the algorithm of Gill and von
Hippel (12).
Nucleotide sequence accession numbers.
The L1c, L1d, and L1e
sequences from isolates K279a, J675a, and N531, respectively, were
submitted to the EMBL database and have been given accession numbers
AJ251814, AJ251815, and AJ272109, respectively. The L2b, L2c, and L2d
sequences from the same three isolates, respectively, were submitted to
the EMBL database and have been given accession numbers AJ251816,
AJ251817, and AJ272110, respectively.
 |
RESULTS |
Allelic variation among L1
-lactamase genes in S. maltophilia.
The L1 genes in 10 clinical isolates of
S. maltophilia, recovered as PCR amplicons, were sequenced.
Three distinct sequences were recovered (Fig.
1; Table 1), typified by L1
from isolates K279a (L1c), J675a (L1d), and N531(L1e). The predicted
amino acid sequences of the L1 variant proteins and their alignments
with two previously published L1 sequences, L1a (30) and
L1b (24), are shown (Fig. 1). The L1c, L1d, and L1e genes
are 12, 8, and 20% divergent from L1a, respectively, and
the encoded proteins are 11, 8, and 19% divergent from L1a,
respectively. There was a similar range of divergence among all of the
proteins (Fig. 1B).

View larger version (62K):
[in this window]
[in a new window]
|
FIG. 1.
Alignment of L1 amino acid sequences. Both strands of
the L1-FULL PCR products from all 10 S. maltophilia isolates
were sequenced as described in Materials and Methods. The predicted
amino acid sequences of L1c, L1d, and L1e are novel, and in panel A
they are aligned with the previously published L1 amino acid sequences,
L1a (30) and L1b (24). All differences from
L1a are shaded. (B) Percent divergence of the L1 proteins compared to
each other.
|
|
Allelic variation among L2
-lactamase genes in S. maltophilia.
An analysis of the L2 genes of the same
isolates also gave three distinct sequences, again typified by the
sequences obtained from isolates K279a, J675a, and N531, named L2b,
L2c, and L2d, respectively (Fig. 2; Table
1). Isolates with the same L2 allele also have common L1 alleles (Table
1). The L2b, L2c, and L2d genes are 9, 4, and 25% divergent from
L2a (31), respectively, and the L2 proteins are
7, 5, and 32% divergent from L2a, respectively, with a similar range
of divergence among all of the L2 proteins (Fig. 2B).

View larger version (64K):
[in this window]
[in a new window]
|
FIG. 2.
Alignments of L2 amino acid sequences. Both strands of
the L2-FULL PCR products from all 10 S. maltophilia isolates
were sequenced as described in Materials and Methods. The predicted
amino acid sequences of L2b, L2c, and L2d are novel, and in panel A
they are aligned with the previously published L2a amino acid sequence
(31). All differences from L2a are shaded. (B) Divergence
among the L2 proteins.
|
|
Allelic variation among 16S rRNA genes in S. maltophilia.
To determine the phylogenetic divergences among
the 10 strains, 500 bp of the hypervariable section of the 16S rRNA
gene in each strain was amplified by PCR and sequenced. The chosen
sequence is one in which maximum variation would be expected
(16). All 10 sequences were found to be essentially the
same and showed less than 1% divergence from each other and from the
type sequence in the EMBL database (accession number AB008509) (Table
1). In fact, only six variant nucleotides were detected (Table 1), and
the exact distribution of alleles divided the isolates into the same
three groupings that were defined by the L1 and L2 alleles (Table 1).
Kinetic analysis of the novel L1
-lactamases.
The L1a gene
and the three novel L1 genes were separately cloned into an E. coli expression vector (see Materials and Methods), and the level
of imipenem hydrolysis in extracts of E. coli transformed with the recombinant plasmids was analyzed (i.e., clones of ether L1a,
L1c, L1d, or L1e). The specific activity of imipenem hydrolysis in
extracts of the L1c and L1d clones was approximately equal to that in
extracts of the L1a clone, but extracts of the L1e clone displayed
markedly lower rates of imipenem hydrolysis. Because of these
differences in hydrolytic activity and the degree of sequence
divergence between L1a and L1e, some of the kinetic parameters of L1e
were studied in more detail. The cloned L1a and L1e were overexpressed,
purified, and analyzed separately but in parallel for comparison. The
purity (>99%) and monomeric molecular size (29 kDa) of each enzyme
was confirmed by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis. In addition, electrospray mass spectrometry was
performed, and this revealed a monomeric molecular mass of 28, 726 Da
for L1a (predicted mass, 29, 122 Da) and 29, 613 Da for L1e (predicted
mass, 29, 974). In both cases, the L1 peak was sharp and represented
more than 95% of the total protein. The Km and
kcat values for hydrolysis of nitrocefin and
imipenem determined for the two enzymes, which were markedly different, are shown in Table 2.
Locations of the L1 and L2
-lactamase genes in S. maltophilia.
Each of the 10 S. maltophilia
isolates was found to possess a large plasmid, although the yield of
plasmid DNA obtained varied considerably from one isolate to another
(Fig. 3A). The plasmids were all
estimated to be approximately 200 kb. When 5 µl of these plasmid
preparations was used as the template DNA in PCR with a primer set
designed to amplify the L1 gene, a product of a size consistent with
that of the target sequence was obtained in each case (Fig. 3B) and the
intensity of the product band was proportional to the amount of plasmid
DNA in each preparation (cf. Fig. 3A and B). Similarly, in
plasmid-primed reactions with a primer set designed to amplify the L2
gene, products of a size consistent with that targeted were also
obtained (Fig. 3C). To eliminate the possibility that the results
simply reflected chromosomal contamination in the plasmid preparations,
multiplex PCR analysis with two sets of primers in the same reaction
was performed. In the first multiplex system, one primer pair was that
used to amplify the L1 gene; the second targeted a sequence encoding
part of the 16S rRNA molecule (Fig. 4A).
When the template provided was total genomic DNA from one of the
isolates, both the expected PCR products were obtained (Fig.
4A, lane G). In contrast, when the
genomic DNA was replaced by plasmid DNA from the same strain, only the L1 gene PCR product was obtained (Fig. 4A, lane P). The same pattern of
results was found with DNA from all 10 isolates (data not shown). In
the second multiplex system, one primer pair amplified part of the L2
gene, while the second primer pair was directed to the S. maltophilia dipeptidyl peptidase IV gene (15). When
the template provided for the PCR was genomic DNA from one of the
isolates, two products with sizes consistent with those of the expected amplimers were clearly visible in the agarose gel (Fig. 4B, lane G).
Again, when genomic DNA was replaced by plasmid DNA in the reaction
mix, only one product, that expected as the result of L2 gene
amplification, was obtained (Fig. 4B, lane P). The results indicate
that both the L1 and L2
-lactamases are encoded on the DNA in each
of the plasmid preparations, while the 16S rRNA and dipeptidyl
peptidase IV genes are not.

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 3.
PCR to show that the L1 and L2 genes of S. maltophilia are plasmid encoded. Plasmids were isolated from 1.5 ml of an overnight culture of S. maltophilia strains 1 to 10 (lanes 1 to 10, respectively, in each panel). (Table 1), (A) A total of
5 µl of the plasmid preparation was resolved by using a 0.8% agarose
gel. (B and C) A total of 5 µl of the plasmid preparation was used as
a template for PCR with the L1-FULL (B) or L2-FULL (C) primer sets.
Primer sequences and PCR conditions are described in Materials and
Methods. (B and C) A total of 10 µl of the PCR product was resolved
by using a 1.2% agarose gel. DNA molecular size markers (1 kb plus
ladder; Life Technologies Ltd., Paisley, United Kingdom) were run in
parallel (lanes M) to check the sizes of the PCR products. The figures
are photographs of the resultant ethidium bromide-stained gels under UV
irradiation.
|
|

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 4.
Assessment of chromosomal DNA contamination of plasmid
preparations by multiplex PCR. (A) Multiplex PCR was performed with 5 µl of plasmid preparation (lane P) or 20 µl of genomic DNA (lane G)
(see Materials and Methods) with the L1-FULL and rDNA primer sets
(Materials and Methods). (B) Multiplex PCR was performed with the
L2-MID and D-PEP primer sets. The L2-MID primers were used instead of
the L2-FULL primers because of the similarity in size between the
L2-FULL and D-PEP amplicons. The PCR was performed as described in
Materials and Methods, and PCR products were separated and visualized
as described in the legend to Fig. 3. Lanes M, DNA molecular size
markers.
|
|
 |
DISCUSSION |
The L1 and L2
-lactamase genes of S. maltophilia are
encoded on a plasmid-like element.
Acquired
-lactamase
production is a common feature of clinical isolates of gram-negative
bacteria, a reflection of the high levels of consumption of
-lactam
antibiotics both in hospitals and in the community. Many of the genes
for these enzymes are not intrinsic to the species in which they have
been found; rather, they have been acquired by horizontal transfer on
plasmids, transposons, and integrons (3, 4). In general,
production of such enzymes is not regulated (5, 8). In
contrast, several gram-negative bacteria of clinical importance produce
at least one
-lactamase intrinsic to the species (5,
8). Expression of these enzymes is often regulated, and
inducible
-lactamase expression by a gram-negative species has been
considered indicative of chromosomally encoded systems
(5). In the present study we have shown that the L1 and L2
-lactamases of S. maltophilia are encoded on plasmid-like elements in all isolates examined. It remains to be seen if the control
system(s) is also encoded on the same elements. We refer to the DNA
molecules carrying the L1 and L2 genes as plasmids simply because they
were isolated by a standard plasmid isolation technique. However, since
all the isolates examined in this study carry the plasmid-like molecule
and all these molecules encode
-lactamase genes that are considered
to be intrinsic to S. maltophilia (8, 10, 18, 24, 30,
31), it may be more accurate to consider these elements as part
of a fragmented chromosome. This interpretation is consistent with
another report that S. maltophilia possesses a fragmented
chromosome (16). We have not determined if the
plasmid-like elements in the isolates examined are related, although
this seems probable.
The L1 and L2
-lactamase genes of S. maltophilia
show considerable allelic variations.
The existence of different
active isoforms of an enzyme arising from allelic variation is a
well-established phenomenon and provides the basis of multilocus enzyme
electrophoresis bacterial typing systems (19). Isoelectric
focusing analysis of both the L1 and the L2
-lactamases of different
isolates of S. maltophilia has indicated allelic variation
of both the L1 and the L2
-lactamase genes of S. maltophilia (10, 20), and two published sequences for
the L1 gene show more than 10% divergence (24, 30). While DNA hybridization studies and 16S rRNA gene analysis of S. maltophilia isolates indicate that the species, as presently
constituted, contains strains that show up to 30% divergence (7,
13), there was no information as to whether the observed and
implied sequence variation seen in previous studies of the L1 and the L2 genes and their products reflects the genetic drift within the
species as a whole.
In the study described here we have shown that in some strains of
S. maltophilia, the L1 gene has undergone a considerable degree of sequence alteration (between 8 and 20% from L1a).
A similar degree of change is also seen in the L2 genes of the same strains (between 4 and 25% from L2a), indicative of
significant strain divergence. Surprisingly, these high levels of
sequence variation were not reflected as differences between the 16S
rRNA genes from the same isolates for which the extent of genetic drift was less than 1% (Table 1). Importantly, these rRNA gene sequencing data have confirmed the species identification of each isolate used
(Table 1).
The discrepancy between the degrees of divergence among the L1 and L2
genes compared with that seen for their associated 16S rRNA genes was
unexpected. If the sequence changes recorded in this study have
occurred by a step-by-step process, then the extremes for the L1 and L2
genes recorded here suggest that the allelic variants have been
diverging for some considerable time. In contrast, the 16S rRNA
sequence data mean that there has been little genetic drift among the
isolates examined. Accordingly, the variation seen among the
-lactamase genes may reflect some form of accelerated evolution, and
this could argue for an involvement of horizontal gene transfer in the
process. To this end, it may be significant that the
-lactamase
genes are located on a DNA molecule whose location is different from
the location of the 16S rRNA gene.
Effect of allelic drift on activities of the L1 and L2
-lactamases.
Comparison of kinetic data for L1a and L1e shows
that L1e is a less efficient enzyme with a significantly lower
kcat/Km for both
nitrocefin and imipenem (Table 2). It is important that the L1a
kinetics of nitrocefin hydrolysis have been reported previously (using
a different expression-purification procedure) (9), and
within error, they are equivalent to the data reported in Table 2.
Structural determination of L1a (29) has led to the
putative identification of key residues involved in binding of
substrate and enzyme catalysis, including an extended loop between
residues 116 and 137 (in particular, F124 and I128) (29,
30). Changes in residues adjacent to these amino acids are
likely to distort their position and/or orientation, affecting the
kinetic parameters of the enzyme. Interestingly, the amino acid
sequence of L1e highlights such changes, namely, G127E and Y130F (Fig.
1), which are predicted to affect substrate docking and therefore lead
to weaker binding of substrates. In addition to these changes, the L1e
sequence reveals a change (noted in boldface) in one of the zinc
binding motifs, from HAHADH (residues 84 to 89 [29,
30]) to HAHTDH (Fig. 1). This A87T substitution may
distort the geometry of the histidines, affecting the coordination to
one or both of the zinc ions. This in turn is likely to affect the coordination of water molecules, particularly WAT1, responsible for the
nucleophilic attack on the
-lactam ring (29) and will inevitably have some bearing on the kcat of the
enzyme. In contrast to the kinetic differences seen among the L1
enzymes, preliminary analysis suggests that the four L2 enzymes have
similar Km and kcat
values with respect to nitrocefin hydrolysis (data not shown). Even
though the sequences of the four enzymes are divergent (Fig. 2), the
key residues (STFK and SDN) are conserved and changes in the residues
surrounding these motifs are conservative (Fig. 2). Thus, it is
probable that several complementary changes have taken place to allow
two similar structures to evolve, but without a published L2 crystal
structure, this hypothesis cannot be tested at present.
Conclusions.
The driving force behind the accelerated
evolution of
-lactamase genes in S. maltophilia is
unknown, but it is possible that it represents, in part, the use of
-lactam antibiotics. The result might be the selection of enzyme
variants better able to provide protection for the cell, and this
process may continue in the future.
 |
ACKNOWLEDGMENTS |
This work was funded in part by a grant from the Wellcome Trust
to P.M.B. and T.R.W. C.S.H. is in receipt of a Biotechnology and
Biological Sciences Research Council CASE studentship in collaboration with SmithKline Beecham Pharmaceuticals. We also thank the British Society for Antimicrobial Chemotherapy for continued group support.
We thank E. Williamson, Bristol Royal Infirmary, Bristol, United
Kingdom, for donating the clinical isolates used and J. Jury and R. Murry, Department of Biochemistry, University of Bristol, for
performing the DNA sequencing.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Pathology and Microbiology, University of Bristol, School of Medical Sciences, University Walk, Bristol BS8 1TD, United Kingdom. Phone: (44)
(117) 9287541. Fax: (44) (117) 9287896. E-mail:
Matthewb.Avison{at}bris.ac.uk.
 |
REFERENCES |
| 1.
|
Alonso, A., and J. I. Martinez.
1997.
Multiple antimicrobial resistance in Stenotrophomonas maltophilia.
Antimicrob. Agents Chemother.
41:1140-1142[Abstract].
|
| 2.
|
Avison, M. B.,
P. M. Bennett, and T. R. Walsh.
2000.
-Lactamase expression in Plesiomonas shigelloides.
J. Antimicrob Chemother.
45:877-880[Abstract/Free Full Text].
|
| 3.
|
Bennett, P. M.
1995.
The spread of drug resistance, p. 317-344.
In
S. Baumberg, J. P. W. Young, E. M. H. Wellington, and J. R. Saunders (ed.), Population genetics of bacteria. Cambridge University Press, Cambridge, United Kingdom.
|
| 4.
|
Bennett, P. M.
1999.
Integrons and gene cassettes: a genetic construction kit for bacteria.
J. Antimicrob. Chemother.
41:1-4.
|
| 5.
|
Bennett, P. M., and I. P. Chopra.
1992.
Molecular basis of -lactamase induction in bacteria.
Antimicrob. Agents Chemother.
37:27-32.
|
| 6.
|
Benson, K. K.,
J. K. Raddatz, and J. C. Rotshafer.
1996.
Stenotrophomonas maltophilia: a clinical perspective.
J. Infect. Dis. Pharm.
2:1-14.
|
| 7.
|
Berg, G.,
N. Roskof, and K. Smalla.
1999.
Genotypic and phenotypic relationships between clinical and environmental isolates of Stenotrophomonas maltophilia.
J. Clin. Microbiol.
37:3594-3600[Abstract/Free Full Text].
|
| 8.
|
Bush, K.,
G. A. Jacoby, and A. A. Medeiros.
1995.
A functional classification scheme for -lactamases and its correlation with molecular structure.
Antimicrob. Agents Chemother.
39:1211-1233[Medline].
|
| 9.
|
Crowder, M. W.,
T. R. Walsh,
L. Banovic,
M. Pettit, and J. Spencer.
1998.
Overexpression, purification, and characterization of the cloned metallo- -lactamase L1 from Stenotrophomonas maltophilia.
Antimicrob. Agents Chemother.
42:921-926[Abstract/Free Full Text].
|
| 10.
|
Denton, M.,
V. Keer, and P. M. Hawkey.
1999.
Correlation between genotype and -lactamases of clinical and environmental strains of Stenotrophomonas maltophilia.
J. Antimicrob. Chemother.
43:555-558[Abstract/Free Full Text].
|
| 11.
|
Fujita, J.,
I. Yamadori,
G. Xu,
S. Hojo,
K. Negayama,
H. Miyawaski,
J. Yamaji, and J. Takahara.
1996.
Clinical features of Strenotrophomonas maltophilia pneumonia in immunocompromised patients.
Respir. Med.
90:35-38[CrossRef][Medline].
|
| 12.
|
Gill, S. C., and P. H. von Hippel.
1989.
Calculation of protein extinction coefficients from amino acid sequence data.
Anal. Biochem.
182:319-326[CrossRef][Medline].
|
| 13.
|
Hauben, L.,
L. Vauterin,
E. R. Moore,
B. Hoste, and J. Swings.
1999.
Genomic diversity of the genus Stenotrophomonas.
Int. J. Syst. Bacteriol.
49:1749-1760[Abstract/Free Full Text].
|
| 14.
|
Jones, M. E.,
M. B. Avison,
E. Damdinsuren,
A. P. MacGowan, and P. M. Bennett.
1994.
Heterogeneity at the -lactamase structural gene ampC amongst Citrobacter spp. assessed by polymerase chain reaction analysis: potential for typing at a molecular level.
J. Med. Microbiol.
41:209-214[Abstract].
|
| 15.
|
Kabashima, T.,
K. Ito, and T. Yoshimoto.
1996.
Dipeptidyl peptidase IV from Xanthomonas maltophilia: sequencing and expression of the enzyme gene and characterisation of the expressed enzyme.
J. Biochem.
120:1111-1117[Abstract/Free Full Text].
|
| 16.
|
Lee, N.-R.,
M.-O. Hwang,
G.-H. Jung,
Y.-S. Kim, and K.-H. Min.
1996.
Physical structure and expression of the alkBA encoding alkane hydroxylase and rubredoxin reductase from Pseudomonas maltophilia.
Biochem. Biophys. Res. Commun.
218:17-21[CrossRef][Medline].
|
| 17.
|
LiPuma, J. J.,
B. J. Dulaney,
J. D. McManamin,
P. W. Whitby,
T. L. Stull,
T. Coenye, and P. Vandamme.
1999.
Development of rRNA-based PCR assays for identification of Burkholderia cepacia complex isolates recovered from cystic fibrosis patients.
J. Clin. Microbiol.
37:3167-3170[Abstract/Free Full Text].
|
| 18.
|
Paton, R.,
R. S. Miles, and S. G. B. Amyes.
1994.
Biochemical properties of inducible -lactamases from Xanthomonas maltophilia.
Antimicrob. Agents Chemother.
38:2143-2149[Abstract/Free Full Text].
|
| 19.
|
Payne, D. J.,
R. Cramp,
J. H. Bateson,
J. Neale, and D. Knowles.
1994.
Rapid identification of metallo- and serine -lactamases.
Antimicrob. Agents Chemother.
38:991-996[Abstract/Free Full Text].
|
| 20.
|
Pradhananga, S. L.,
P. J. Rowling,
I. N. Simpson, and D. J. Payne.
1996.
Sensitivity of L2 type -lactamases from Stenotrophomonas maltophilia to serine active site -lactamase inhibitors.
J. Antimicrob. Chemother.
37:394-396[Free Full Text].
|
| 21.
|
Rosta, S., and H. Mett.
1988.
Physiological studies of the regulation of -lactamase expression in Pseudomonas maltophilia.
J. Bacteriol.
171:483-487.
|
| 22.
|
Saino, Y.,
F. Kobayashi,
M. Inoue, and S. Mitsuhashi.
1982.
Purification and properties of an inducible penicillin -lactamase isolated from Pseudomonas maltophilia.
Antimicrob. Agents Chemother.
22:564-570[Abstract/Free Full Text].
|
| 23.
|
Saino, Y.,
M. Inoue, and S. Mitsuhashi.
1984.
Purification and properties of an inducible cephalosporinase from Pseudomonas maltophilia.
Antimicrob. Agents Chemother.
25:362-365[Abstract/Free Full Text].
|
| 24.
|
Sanschagrin, F.,
J. Dufresne, and R. Levesque.
1998.
Molecular heterogeneity of the L1 metallo- -lactamase family from Stenotrophomonas maltophilia.
Antimicrob. Agents Chemother.
42:1245-1248[Abstract/Free Full Text].
|
| 25.
|
Sanyal, S. C., and E. M. Mokaddas.
1999.
The increase in carbapenem use and emergence of Stenotrophomonas maltophilia as an important nosocomial pathogen.
J. Chemother.
11:28-33[Medline].
|
| 26.
|
Suzuki, Y.,
M. Koguchi,
S. Takana,
S. Fakayama,
R. Ishihara,
K. Deguchi,
S. Oda,
Y. Nakane, and T. Fukumoto.
1995.
Frequency of clinical isolation of glucose non-fermentive gram-negative rods and their susceptibilities to antimicrobial agents.
Jpn. J. Antibiot.
48:1264-1273[Medline].
|
| 27.
|
Traub, W. H.,
B. Leonhard, and D. Bauer.
1998.
Stenotrophomonas (Xanthomonas) maltophilia: in vitro susceptibility to selected antimicrobial drugs, single and combined, with or without defibrinated human blood.
Chemotherapy (Basel)
44:293-304.
|
| 28.
|
Ubeda, P.,
M. Salavert,
S. Giner,
I. Jarque,
J. Lopez-Aldeguer,
C. Perez-Belles, and M. Gobernado.
1998.
Bacteraemia from Stenotrophomonas maltophilia: clinical epidemiological study and resistance profile.
Rev. Esp. Quimioter.
11:205-215[Medline].
|
| 29.
|
Ullah, J. H.,
T. R. Walsh,
I. A. Taylor,
D. C. Emery,
C. S. Verma,
S. J. Gamblin, and J. Spencer.
1998.
The crystal structure of the L1 metallo- -lactamase from Stenotrophomonas maltophilia at 1.7 Å resolution.
J. Mol. Biol.
284:125-136[CrossRef][Medline].
|
| 30.
|
Walsh, T. R.,
L. Hall,
S. J. Assinder,
W. W. Nichols,
S. J. Cartwright,
A. P. MacGowen, and P. M. Bennett.
1994.
Sequence analysis of the L1 metallo- -lactamase from Xanthomonas maltophilia.
Biochim. Biophys. Acta
1218:199-201[Medline].
|
| 31.
|
Walsh, T. R.,
A. P. MacGowen, and P. M. Bennett.
1997.
Sequence analysis and enzyme kinetics of the of the L2 -lactamase from Stenotrophomonas maltophilia.
Antimicrob. Agents Chemother.
41:1460-1464[Abstract].
|
Antimicrobial Agents and Chemotherapy, February 2001, p. 413-419, Vol. 45, No. 2
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.2.413-419.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Samuelsen, O., Castanheira, M., Walsh, T. R., Spencer, J.
(2008). Kinetic Characterization of VIM-7, a Divergent Member of the VIM Metallo-{beta}-Lactamase Family. Antimicrob. Agents Chemother.
52: 2905-2908
[Abstract]
[Full Text]
-
Falagas, M. E., Valkimadi, P.-E., Huang, Y.-T., Matthaiou, D. K., Hsueh, P.-R.
(2008). Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. J Antimicrob Chemother
0: dkn301v1-6
[Abstract]
[Full Text]
-
Okazaki, A., Avison, M. B.
(2008). Induction of L1 and L2 {beta}-Lactamase Production in Stenotrophomonas maltophilia Is Dependent on an AmpR-Type Regulator. Antimicrob. Agents Chemother.
52: 1525-1528
[Abstract]
[Full Text]
-
Hu, R.-M., Huang, K.-J., Wu, L.-T., Hsiao, Y.-J., Yang, T.-C.
(2008). Induction of L1 and L2 {beta}-Lactamases of Stenotrophomonas maltophilia. Antimicrob. Agents Chemother.
52: 1198-1200
[Abstract]
[Full Text]
-
Okazaki, A., Avison, M. B.
(2007). Aph(3')-IIc, an Aminoglycoside Resistance Determinant from Stenotrophomonas maltophilia. Antimicrob. Agents Chemother.
51: 359-360
[Abstract]
[Full Text]
-
Gould, V. C., Avison, M. B.
(2006). SmeDEF-mediated antimicrobial drug resistance in Stenotrophomonas maltophilia clinical isolates having defined phylogenetic relationships. J Antimicrob Chemother
57: 1070-1076
[Abstract]
[Full Text]
-
Walther-Rasmussen, J., Hoiby, N.
(2006). OXA-type carbapenemases. J Antimicrob Chemother
57: 373-383
[Abstract]
[Full Text]
-
Gould, V. C., Okazaki, A., Avison, M. B.
(2006). {beta}-Lactam resistance and {beta}-lactamase expression in clinical Stenotrophomonas maltophilia isolates having defined phylogenetic relationships. J Antimicrob Chemother
57: 199-203
[Abstract]
[Full Text]
-
Furushita, M., Okamoto, A., Maeda, T., Ohta, M., Shiba, T.
(2005). Isolation of Multidrug-Resistant Stenotrophomonas maltophilia from Cultured Yellowtail (Seriola quinqueradiata) from a Marine Fish Farm. Appl. Environ. Microbiol.
71: 5598-5600
[Abstract]
[Full Text]
-
Walsh, T. R., Toleman, M. A., Poirel, L., Nordmann, P.
(2005). Metallo-{beta}-Lactamases: the Quiet before the Storm?. Clin. Microbiol. Rev.
18: 306-325
[Abstract]
[Full Text]
-
Castanheira, M., Toleman, M. A., Jones, R. N., Schmidt, F. J., Walsh, T. R.
(2004). Molecular Characterization of a {beta}-Lactamase Gene, blaGIM-1, Encoding a New Subclass of Metallo-{beta}-Lactamase. Antimicrob. Agents Chemother.
48: 4654-4661
[Abstract]
[Full Text]
-
Gould, V. C., Okazaki, A., Howe, R. A., Avison, M. B.
(2004). Analysis of sequence variation among smeDEF multi drug efflux pump genes and flanking DNA from defined 16S rRNA subgroups of clinical Stenotrophomonas maltophilia isolates. J Antimicrob Chemother
54: 348-353
[Abstract]
[Full Text]
-
Sanchez, P., Alonso, A., Martinez, J. L.
(2004). Regulatory Regions of smeDEF in Stenotrophomonas maltophilia Strains Expressing Different Amounts of the Multidrug Efflux Pump SmeDEF. Antimicrob. Agents Chemother.
48: 2274-2276
[Abstract]
[Full Text]
-
Koh, T. H., Wang, G. C. Y., Sng, L.-H.
(2004). IMP-1 and a Novel Metallo-{beta}-Lactamase, VIM-6, in Fluorescent Pseudomonads Isolated in Singapore. Antimicrob. Agents Chemother.
48: 2334-2336
[Abstract]
[Full Text]
-
Avison, M. B., Underwood, S., Okazaki, A., Walsh, T. R., Bennett, P. M.
(2004). Analysis of AmpC {beta}-lactamase expression and sequence in biochemically atypical ceftazidime-resistant Enterobacteriaceae from paediatric patients. J Antimicrob Chemother
53: 584-591
[Abstract]
[Full Text]
-
Barbolla, R., Catalano, M., Orman, B. E., Famiglietti, A., Vay, C., Smayevsky, J., Centron, D., Pineiro, S. A.
(2004). Class 1 Integrons Increase Trimethoprim-Sulfamethoxazole MICs against Epidemiologically Unrelated Stenotrophomonas maltophilia Isolates. Antimicrob. Agents Chemother.
48: 666-669
[Abstract]
[Full Text]
-
Avison, M. B., Niumsup, P., Nurmahomed, K., Walsh, T. R., Bennett, P. M.
(2004). Role of the 'cre/blr-tag' DNA sequence in regulation of gene expression by the Aeromonas hydrophila {beta}-lactamase regulator, BlrA. J Antimicrob Chemother
53: 197-202
[Abstract]
[Full Text]
-
Kirby, J. T., Sader, H. S., Walsh, T. R., Jones, R. N.
(2004). Antimicrobial Susceptibility and Epidemiology of a Worldwide Collection of Chryseobacterium spp.: Report from the SENTRY Antimicrobial Surveillance Program (1997-2001). J. Clin. Microbiol.
42: 445-448
[Abstract]
[Full Text]
-
Murphy, T. A., Simm, A. M., Toleman, M. A., Jones, R. N., Walsh, T. R.
(2003). Biochemical Characterization of the Acquired Metallo-{beta}-Lactamase SPM-1 from Pseudomonas aeruginosa. Antimicrob. Agents Chemother.
47: 582-587
[Abstract]
[Full Text]
-
Walsh, T. R., Bolmstrom, A., Qwarnstrom, A., Gales, A.
(2002). Evaluation of a New Etest for Detecting Metallo-{beta}-Lactamases in Routine Clinical Testing. J. Clin. Microbiol.
40: 2755-2759
[Abstract]
[Full Text]
-
Simm, A. M., Higgins, C. S., Carenbauer, A. L., Crowder, M. W., Bateson, J. H., Bennett, P. M., Clarke, A. R., Halford, S. E., Walsh, T. R.
(2002). Characterization of Monomeric L1 Metallo-beta -lactamase and the Role of the N-terminal Extension in Negative Cooperativity and Antibiotic Hydrolysis. J. Biol. Chem.
277: 24744-24752
[Abstract]
[Full Text]
-
Avison, M. B., Higgins, C. S., Ford, P. J., von Heldreich, C. J., Walsh, T. R., Bennett, P. M.
(2002). Differential regulation of L1 and L2 {beta}-lactamase expression in Stenotrophomonas maltophilia. J Antimicrob Chemother
49: 387-389
[Abstract]
[Full Text]
-
Zhang, L., Li, X.-Z., Poole, K.
(2001). SmeDEF Multidrug Efflux Pump Contributes to Intrinsic Multidrug Resistance in Stenotrophomonas maltophilia. Antimicrob. Agents Chemother.
45: 3497-3503
[Abstract]
[Full Text]